NO943804L - Fremgangsmåte for behandling av HIV-seropositive individer med diett-myse - Google Patents

Fremgangsmåte for behandling av HIV-seropositive individer med diett-myse

Info

Publication number
NO943804L
NO943804L NO943804A NO943804A NO943804L NO 943804 L NO943804 L NO 943804L NO 943804 A NO943804 A NO 943804A NO 943804 A NO943804 A NO 943804A NO 943804 L NO943804 L NO 943804L
Authority
NO
Norway
Prior art keywords
mites
dietary
seropositive individuals
treating hiv
hiv seropositive
Prior art date
Application number
NO943804A
Other languages
English (en)
Other versions
NO317795B1 (no
NO943804D0 (no
Inventor
Phil Gold
Gustavo Bounous
Original Assignee
Immunotec Res Corp Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunotec Res Corp Ltd filed Critical Immunotec Res Corp Ltd
Publication of NO943804D0 publication Critical patent/NO943804D0/no
Publication of NO943804L publication Critical patent/NO943804L/no
Publication of NO317795B1 publication Critical patent/NO317795B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/19—Dairy proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/20—Milk; Whey; Colostrum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Microbiology (AREA)
  • Nutrition Science (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NO19943804A 1992-04-10 1994-10-07 Anvendelse av vesentlig udenaturert myseproteinkonsentrat for fremstilling av en farmasoytisk blanding for behandling av HIV-seropositive individer. NO317795B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/866,756 US5456924A (en) 1988-12-23 1992-04-10 Method of treatment of HIV-seropositive individuals with dietary whey proteins
PCT/CA1993/000107 WO1993020831A1 (en) 1992-04-10 1993-03-22 Method of treatment of hiv-seropositive individuals with dietary whey proteins

Publications (3)

Publication Number Publication Date
NO943804D0 NO943804D0 (no) 1994-10-07
NO943804L true NO943804L (no) 1994-10-07
NO317795B1 NO317795B1 (no) 2004-12-13

Family

ID=25348339

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19943804A NO317795B1 (no) 1992-04-10 1994-10-07 Anvendelse av vesentlig udenaturert myseproteinkonsentrat for fremstilling av en farmasoytisk blanding for behandling av HIV-seropositive individer.

Country Status (19)

Country Link
US (1) US5456924A (no)
EP (1) EP0634934B1 (no)
JP (1) JP2738592B2 (no)
KR (1) KR100297959B1 (no)
CN (1) CN1070371C (no)
AT (1) ATE187335T1 (no)
AU (1) AU687731B2 (no)
CA (1) CA2090186C (no)
CZ (1) CZ283386B6 (no)
DE (1) DE69327236T2 (no)
DK (1) DK0634934T3 (no)
ES (1) ES2143503T3 (no)
IL (1) IL105339A (no)
MX (1) MX9302057A (no)
NO (1) NO317795B1 (no)
NZ (1) NZ251271A (no)
TW (1) TW384223B (no)
WO (1) WO1993020831A1 (no)
ZA (1) ZA932526B (no)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6241983B1 (en) 1994-10-28 2001-06-05 Metagenics, Inc. Bacteria-and fiber-containing composition for human gastrointestinal health
US5531989A (en) 1994-10-28 1996-07-02 Metagenics, Inc. Immunoglobulin and fiber-containing composition for human gastrointestinal health
US5985275A (en) * 1995-04-12 1999-11-16 New York Blood Center β-Lactoglobulin modified with aromatic anhydride compound for preventing HIV infection
CA2165937A1 (en) * 1995-05-09 1996-11-10 Immunotec Research Corporation Ltd. Process for producing an undenatured whey protein concentrate
US5914255A (en) * 1996-03-06 1999-06-22 Grae; Joel B. Temperature shock method and apparatus
AU1707197A (en) * 1996-03-20 1997-10-10 New York Blood Center, Inc., The Methods of treating herpes or chlamydia
US5952009A (en) * 1996-03-20 1999-09-14 New York Blood Center Methods for preventing the transmission of or treating patients infected with herpesvirus
US6262019B1 (en) 1998-04-30 2001-07-17 Vit-Immune, L. C. Method of treatment of glutathione deficient mammals
ATE322275T1 (de) * 1998-06-10 2006-04-15 Albert B Crum Vorbeugender und therapeutischer nahrungsmittelzusatz zur schaffung/erhaltung einer die gesundheit schützenden darmmikroflora und zur stärkung des immunsystems
US6667063B2 (en) 1998-06-10 2003-12-23 Albert Crum Nutritional or therapeutic supplement and method
US6203805B1 (en) 1998-11-10 2001-03-20 Color Access, Inc. Topical compositions containing whey proteins
EP1372641A4 (en) 2001-03-05 2004-08-25 Stephen P Ernest ENTERAL FORMULATION
US6503506B1 (en) * 2001-08-10 2003-01-07 Millenium Biotechnologies, Inc. Nutrient therapy for immuno-compromised patients
ES2451618T3 (es) 2001-12-20 2014-03-28 Biolactis Inc. Matriz de proteína maleable y usos de estas
FR2840318B1 (fr) * 2002-05-29 2004-12-03 Quoc Kiet Pham Nouveaux sulfolipides antiretroviraux extraits de spirulines, leur procede d'obtention, les compositions les contenant et leur utilisation comme inhibiteurs de la transcriptase inverse des virus vih
FR2889067B1 (fr) * 2005-07-29 2011-11-11 Cie Laitiere Europeenne "utilisation d'une fraction proteique laitiere pour preparer une composition amincissante et/ou ameliorant la composition corporelle"
DE102006052504A1 (de) 2006-11-06 2008-05-08 Temper, Rupert Verfahren zum Herstellen eines Mittels gegen eine Infektionskrankheit
US20080119386A1 (en) * 2006-11-22 2008-05-22 Carl Germano Nutritional formula for athletes' recovery
AP2009004963A0 (en) * 2007-02-06 2009-10-31 Cymcorp Internat Inc Novel non-toxic composition and method of using such for treating a degenerative or an immune systemrelated disease
US20100069288A1 (en) * 2008-09-12 2010-03-18 Wulf Droge Use of cysteine-rich whey derived protein in patients receiving chemotherapy or radiotherapy to improve patient survival
JP2013079216A (ja) * 2011-10-04 2013-05-02 Snow Brand Milk Products Co Ltd 感覚改善剤
JP6234777B2 (ja) * 2013-10-31 2017-11-22 株式会社日立製作所 光多値送信器および光トランスポンダ
DE102014001037A1 (de) * 2014-01-25 2015-07-30 Gea Tds Gmbh Verfahren und Vorrichtung zur Reduzierung des Wachstums thermophiler Keime in Magermilch
WO2018057514A1 (en) 2016-09-23 2018-03-29 Immunotec Inc. Compositions for restoring gene expression in neuropsychiatric or neurodegenerative disorders
CA2970699A1 (en) 2017-06-14 2018-12-14 Elizabeth E. Ignowski Compositions for increasing resilience to traumatic brain injury
US11944649B2 (en) 2017-07-31 2024-04-02 Immunotec Inc. Compositions and methods for treatment of autism spectrum disorder

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA858533A (en) * 1970-12-15 Lahav Eitan Polypeptidic antibiotic substances derived from casein by fermentation
FR2565985B1 (fr) * 1984-06-19 1987-09-25 Rhone Poulenc Sante Nouvelles substances biologiquement actives obtenues a partir de la caseine bovine, leur procede de preparation et les compositions qui les contiennent
US4880626A (en) * 1985-01-18 1989-11-14 Mcmichael John Immunotherapeutic methods and compositions for the treatment of diseases of viral origin, including acquired immune deficiency syndrome
US4983387A (en) * 1986-05-19 1991-01-08 Viral Technologies Inc. HIV related peptides, immunogenic antigens, and use therefor as subunit vaccine for AIDS virus
US5030449A (en) * 1988-07-21 1991-07-09 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Synthetic vaccine against AIDS virus
EP0338229B1 (de) * 1988-04-19 1993-06-16 Biotest Pharma Gmbh Präparat mit Antikörperaktivität und breitem Wirkungsspektrum, daraus bestehende oder diese enthaltende Mittel und deren Verwendung zur Behandlung von bakteriell oder toxin-bedingten Erkrankungen und zur Bekämpfung von Protozoen
FI892006L (fi) * 1988-04-29 1989-10-30 Phil Gold Lactalbumin saosom tillaeggsaemne i mat.
CA1338682C (en) * 1988-12-23 1996-10-29 Gustavo Bounous Biologically active undenatured whey protein concentrate as food supplement
CA2007258A1 (en) * 1989-01-11 1990-07-11 Richard L. Jackson Heparin fraction with anti-hiv activity
CA2011299A1 (en) * 1989-03-03 1990-09-03 Franklin Volvovitz Aids therapy
AU645016B2 (en) * 1989-06-02 1994-01-06 Johns Hopkins University School Of Medicine, The Monoclonal antibodies against leukocyte adhesion receptor beta-chain, methods of producing these antibodies and use therefore
CA2022394A1 (en) * 1989-08-07 1991-02-08 Allen I. Oliff Peptide inhibitors of human papilloma virus protein binding to retinoblastoma gene proteins
ATE366311T1 (de) * 1989-12-22 2007-07-15 Hoffmann La Roche Zytotoxischer lymphozyten-reifefaktor 35kd untereinheit und monoklonale antikörper spezifisch dafür
US5112373A (en) * 1991-06-17 1992-05-12 Hung Pham Apparatus for controlling and eliminating vapor emissions at a manicure work station

Also Published As

Publication number Publication date
DK0634934T3 (da) 2000-06-13
CZ246194A3 (en) 1995-04-12
EP0634934B1 (en) 1999-12-08
ES2143503T3 (es) 2000-05-16
EP0634934A1 (en) 1995-01-25
TW384223B (en) 2000-03-11
NO317795B1 (no) 2004-12-13
DE69327236T2 (de) 2000-03-30
AU3881293A (en) 1993-11-18
AU687731B2 (en) 1998-03-05
ATE187335T1 (de) 1999-12-15
WO1993020831A1 (en) 1993-10-28
DE69327236D1 (de) 2000-01-13
CN1070371C (zh) 2001-09-05
ZA932526B (en) 1994-03-09
NZ251271A (en) 1998-05-27
NO943804D0 (no) 1994-10-07
CA2090186C (en) 1999-03-16
JPH07504677A (ja) 1995-05-25
IL105339A (en) 1998-07-15
CN1083704A (zh) 1994-03-16
MX9302057A (es) 1994-07-29
CA2090186A1 (en) 1993-10-11
KR950700752A (ko) 1995-02-20
JP2738592B2 (ja) 1998-04-08
CZ283386B6 (cs) 1998-04-15
US5456924A (en) 1995-10-10
IL105339A0 (en) 1993-08-18
KR100297959B1 (ko) 2001-10-24

Similar Documents

Publication Publication Date Title
NO943804D0 (no) Fremgangsmåte for behandling av HIV-seropositive individer med diett-myse
Kirkman et al. Different enzymic expressions of mutants of human glucose-6-phosphate dehydrogenase
AU1285592A (en) Methods for increasing extracellular adenosine and for stabilizing mast cells
ATE259644T1 (de) Behandlung von hämoglobin enthaltenden erythrozyten mit stickstoffoxyd
Yamashita et al. Response of superoxide anion production by guinea pig eosinophils to various soluble stimuli: comparison to neutrophils
Miller et al. Plasmodium falciparum: thiol status and growth in normal and glucose-6-phosphate dehydrogenase deficient human erythrocytes
Fernandez-Sousa et al. Variation of superoxide dismutases during the development of the fruit fly Ceratitis capitata L
ATE17651T1 (de) Mischung zum verabreichen bei menschen von selenium als spurenelement.
AU652988B2 (en) Method for insuring adequate intracellular glutathione in tissue
AU1138288A (en) Use of human blood coagulation factor xiii for the treatment of ulcerative colitis
Stern et al. Peptidase activity in leucocytes, erythrocytes and plasma of young adult and senile subjects
BAKER et al. Vitamin distribution in red blood cells, plasma, and other body fluids
Sorrell et al. In vivo and in vitro penetration of vitamins into human red blood cells
Kaplay Modified kinetics of erythrocyte membrane Na+ K+ adenosine triphosphatase in protein-energy malnutrition
Scriver et al. NEONATAL TYROSINEMIA (NT) IN THE ESKIMO. RESULT OF A PROTEIN POLYMORPHISM?
Lewis et al. The Selective Membrane Filtration of an ESF-generating Factor (EGF) in the Presence of Erythropoietin (ESF)
Ramakrishnan et al. Studies on the combined and relative influence of dietary protein and riboflavin in flavoprotein enzymes
DE69130483D1 (de) Verbesserter blutersatz
Peters et al. Amino Acids and L-Asparaginase Activity in the Plasma of Owl Monkeys (Aotus trivirgatus)
Alfthan Human selenium status, dietary intake and bioavailability in Finland as assessed by selenium and glutathione peroxidase determinations.
Ikeda et al. O. 64 Taurine augments E. coli induced PMN necrosis in vitro
IOKU Methemoglobin formation from hemoglobin by nitrite ion in the erythrocytes of normal and acatalasemic mice; in vivo and in vitro study
Gentilini et al. O. 67 In vitro glutamine refeeding restores macrophagefunction in malnourished mice
ISHIGURO et al. Effect of Glutathione and Cysteine on Rat Liver Tryptophan Oxygenase Activity
Ivanov EXPERIMENTAL STUDIES OF THE INFLUENCE OF HIGH DOSES OF VITAMINS A AND Е ON THE 5'NUCLEOTIDASE AND ADENYLPYROPHATASE ACTIVITY AND ON THE QUANTITY OF THE THIOL GROUPS IN THE HEART MUSCLE OF WHITE RATS

Legal Events

Date Code Title Description
MK1K Patent expired